Dr. Michael Aberman’s Story Behind XenImmune
Aided by Cure Ventures’ diligent and rigorous approach to company building, we’re pioneering the platform technology of hyperacute rejection to fight cancer and I’m excited to say our lead therapy has shown proof-of-concept in in vitro and in vivo models. With the help of Cure’s seed funding and active collaboration, we continue to generate the data necessary to drive us forward as we seek Series A funding and advance our lead candidate further down the path to the clinic. In the future, I know Cure will be there to support us as we grow and reach new milestones. With Cure, we have more than an investor – they’re a true sweat equity partner working alongside the XenImmune team.
